Topical niclosamide (ATx201) reduces <i>Staphylococcus aureus</i> colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial
Anne Weiss(Novo Nordisk Foundation), Morten Otto Alexander Sommer(Novo Nordisk Foundation)
Cited by 46
Related Papers
Discovery and Characterization of Cas9 Inhibitors Disseminated across Seven Bacterial Phyla
|Cell Host & Microbe|2019|84